Servier and the n-Lorem Foundation have entered a multi-target research collaboration to develop antisense oligonucleotide (ASO) therapies for rare and severe neurodevelopmental disorders. The partnership will combine n-Lorem’s cutting-edge ASO technology platform with Servier’s research and development expertise, with the goal of advancing precision medicine approaches for patients worldwide who currently have few or no treatment options. As part of the agreement, n-Lorem’s research teams will design preclinical ASO candidates targeting disease-causing RNA, which Servier will then move into clinical development.
The collaboration is expected to increase the number of patients n-Lorem can treat and further strengthens Servier’s commitment to rare neurological diseases. The partners aim to extend the reach of precision genetic medicine to people living with rare neurological disorders, including refractory epilepsy, genetically driven autism spectrum disorders, leukodystrophies, peripheral neuropathies, movement disorders and neuromuscular diseases. Servier has framed the alliance as an important step toward its 2030 ambition to deliver innovative treatments in areas of high unmet need in neurology.
Executives from both organizations highlighted the potential of personalized ASO therapies to address the root causes of genetic neurological conditions and tackle previously intractable diseases. Servier’s Global Head of R&D Neurology, Nitza Thomasson, said the collaboration reflects a shared commitment to open, multidisciplinary science aimed at bringing meaningful therapies to patients who have been waiting “for far too long.” n-Lorem Founder, Chairman and CEO Stanley T. Crooke called the partnership a “win, win for patients with rare diseases” and said Servier’s support will help advance ASO technology while contributing to its broader commitment to patients with rare neurological disorders.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!